WO2006046916A1 - Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases - Google Patents
Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases Download PDFInfo
- Publication number
- WO2006046916A1 WO2006046916A1 PCT/SE2005/001610 SE2005001610W WO2006046916A1 WO 2006046916 A1 WO2006046916 A1 WO 2006046916A1 SE 2005001610 W SE2005001610 W SE 2005001610W WO 2006046916 A1 WO2006046916 A1 WO 2006046916A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- optionally substituted
- phenyl
- haloalkyl
- methyl
- Prior art date
Links
- VVNHALFQXYIUSP-UHFFFAOYSA-N CC(C(C=C1)F)C=C1Oc(cc1)ccc1S(NCCCc1ccccc1)(=O)=O Chemical compound CC(C(C=C1)F)C=C1Oc(cc1)ccc1S(NCCCc1ccccc1)(=O)=O VVNHALFQXYIUSP-UHFFFAOYSA-N 0.000 description 1
- AJJFWRKYRXOUBA-UHFFFAOYSA-N CC(COc(cc(cc1)Cl)c1C(N)=O)NS(c1c(C)cc(C)cc1C)(=O)=O Chemical compound CC(COc(cc(cc1)Cl)c1C(N)=O)NS(c1c(C)cc(C)cc1C)(=O)=O AJJFWRKYRXOUBA-UHFFFAOYSA-N 0.000 description 1
- YLMRPFGKBNBQBQ-UHFFFAOYSA-N CC(COc1c(C)cccc1C)NS(c1cc(OC)ccc1)(=O)=O Chemical compound CC(COc1c(C)cccc1C)NS(c1cc(OC)ccc1)(=O)=O YLMRPFGKBNBQBQ-UHFFFAOYSA-N 0.000 description 1
- PBEIKYVPZDJQFR-UHFFFAOYSA-N CC(COc1c(C)cccc1C)NS(c1ccc(C(C)(C)C)cc1)(=O)=O Chemical compound CC(COc1c(C)cccc1C)NS(c1ccc(C(C)(C)C)cc1)(=O)=O PBEIKYVPZDJQFR-UHFFFAOYSA-N 0.000 description 1
- HUALKWKBEMNYTA-UHFFFAOYSA-N CC(COc1c(cccn2)c2ccc1)[NH2+][SH+](c1ccc(-c2n[n](C)c(C(F)(F)F)c2)[s]1)(O)OC Chemical compound CC(COc1c(cccn2)c2ccc1)[NH2+][SH+](c1ccc(-c2n[n](C)c(C(F)(F)F)c2)[s]1)(O)OC HUALKWKBEMNYTA-UHFFFAOYSA-N 0.000 description 1
- CNNDNMRHYTXTBQ-UHFFFAOYSA-N CCC(C)(C)c(cc1)ccc1S(NCCOC1=CC=CCC1C)(=O)=O Chemical compound CCC(C)(C)c(cc1)ccc1S(NCCOC1=CC=CCC1C)(=O)=O CNNDNMRHYTXTBQ-UHFFFAOYSA-N 0.000 description 1
- FNAWLSUOELOBQD-UHFFFAOYSA-N CCCCOc(cc1)ccc1S(NC(C)CCc1ccccc1)(=O)=O Chemical compound CCCCOc(cc1)ccc1S(NC(C)CCc1ccccc1)(=O)=O FNAWLSUOELOBQD-UHFFFAOYSA-N 0.000 description 1
- KUTLISBJXYLBCQ-UHFFFAOYSA-N CCCCOc(cc1)ccc1S(NC(C)COc1c(C)cccc1C)(=O)=O Chemical compound CCCCOc(cc1)ccc1S(NC(C)COc1c(C)cccc1C)(=O)=O KUTLISBJXYLBCQ-UHFFFAOYSA-N 0.000 description 1
- UWXNKLROIMPBIU-HNNXBMFYSA-N C[C@@H](CNc(ccc(S(C)(=O)=O)c1)c1Cl)NS(c1c(C)cc(C)cc1C)(=O)=O Chemical compound C[C@@H](CNc(ccc(S(C)(=O)=O)c1)c1Cl)NS(c1c(C)cc(C)cc1C)(=O)=O UWXNKLROIMPBIU-HNNXBMFYSA-N 0.000 description 1
- JSPFOPNAPMVDEF-JTQLQIEISA-N C[C@@H](COc(ccc(Cl)c1)c1C(N)=O)NS(c(ccc(Br)c1)c1OC(C)(F)F)(=O)=O Chemical compound C[C@@H](COc(ccc(Cl)c1)c1C(N)=O)NS(c(ccc(Br)c1)c1OC(C)(F)F)(=O)=O JSPFOPNAPMVDEF-JTQLQIEISA-N 0.000 description 1
- RJMOFILOVNHBNF-QMMMGPOBSA-N C[C@@H](COc(cccc1)c1C(N)=O)NS(c(cc([s]1)Cl)c1Cl)(=O)=O Chemical compound C[C@@H](COc(cccc1)c1C(N)=O)NS(c(cc([s]1)Cl)c1Cl)(=O)=O RJMOFILOVNHBNF-QMMMGPOBSA-N 0.000 description 1
- JWBOJTQIRMYTKS-VIFPVBQESA-N C[C@@H](COc(cccc1)c1C(N)=O)NS(c1c(C)[n](C(F)F)nc1C)(=O)=O Chemical compound C[C@@H](COc(cccc1)c1C(N)=O)NS(c1c(C)[n](C(F)F)nc1C)(=O)=O JWBOJTQIRMYTKS-VIFPVBQESA-N 0.000 description 1
- NUBSXEUXGJCFQP-HNNXBMFYSA-N C[C@@H](COc1ccc2OCOc2c1)NS(c1c(C)cc(C)cc1C)(=O)=O Chemical compound C[C@@H](COc1ccc2OCOc2c1)NS(c1c(C)cc(C)cc1C)(=O)=O NUBSXEUXGJCFQP-HNNXBMFYSA-N 0.000 description 1
- PGOPISGWLLJINP-NSHDSACASA-N C[C@@H](COc1cccc2c1cccn2)NS(c(c(Cl)cc(I)c1)c1Cl)(=O)=O Chemical compound C[C@@H](COc1cccc2c1cccn2)NS(c(c(Cl)cc(I)c1)c1Cl)(=O)=O PGOPISGWLLJINP-NSHDSACASA-N 0.000 description 1
- OSYLPXDAPVPYGJ-NSHDSACASA-N C[C@@H](COc1cccc2ncccc12)NS(c([s]1)ccc1Cl)(=O)=O Chemical compound C[C@@H](COc1cccc2ncccc12)NS(c([s]1)ccc1Cl)(=O)=O OSYLPXDAPVPYGJ-NSHDSACASA-N 0.000 description 1
- UZPWTPWMSHGTPC-ZDUSSCGKSA-N C[C@@H](COc1cccc2ncccc12)NS(c(c(Cl)c1)c(C)cc1Cl)(=O)=O Chemical compound C[C@@H](COc1cccc2ncccc12)NS(c(c(Cl)c1)c(C)cc1Cl)(=O)=O UZPWTPWMSHGTPC-ZDUSSCGKSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/17—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/18—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms, not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
- C07C311/46—Y being a hydrogen or a carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
- C07C317/36—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atoms of the amino groups bound to hydrogen atoms or to carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/48—Two nitrogen atoms
- C07D251/52—Two nitrogen atoms with an oxygen or sulfur atom attached to the third ring carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/80—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
- C07D317/64—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/34—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- the present invention relates to sulphonamide derivatives, to their use as medicaments (for example in the treatment of an inflammatory disease state), to pharmaceutical compositions comprising them and to processes for preparing them.
- Sulphonamide derivatives are disclosed as antiinflammatories in WO 2004/019935 and WO 2004/050631.
- Pharmaceutically active sulphonamides are also disclosed in Arch. Pharm. (1980) 313 166-173, J.Med. Chem. (2003) 46 64-73, J. Med. Chem (1997) 40 996- 1004, EP 0031954, EP 1190710 (WO 200124786), US 5861401, US 4948809, US3992441 and WO 99/33786.
- non-steroidal compounds interact with the glucocorticoid receptor (GR) and, as a result of this interaction, produce a suppression of inflammation (see, for example, US6323199).
- GR glucocorticoid receptor
- Such compounds can show a clear dissociation between anti ⁇ inflammatory and metabolic actions making them superior to earlier reported steroidal and non-steroidal glucocorticoids.
- the present invention provides further non-steroidal compounds as modulators (for example agonists, antagonists, partial agonists or partial antagonists) of the glucocorticoid receptor capable of having a dissociation between their anti-inflammatory and metabolic actions.
- the present invention provides a compound of formula (I):
- A is phenyl, naphthyl, pyridinyl, furyl, thienyl, isoxazolyl, pyrazolyl, benzthienyl, quinolinyl or isoquinolinyl, and A is optionally substituted by halo, C 1-6 alkyl, C 1-6 alkoxy, C 1-4 alkylthio, C 1-4 fluoroalkyl, C 1-4 fluoroalkoxy, pyridinyloxy, benzyloxy, nitro, cyano, C(O) 2 H, C(O) 2 (C 1-4 alkyl), S(O) 2 (C 1-4 alkyl), S(O) 2 (C 1-4 alkyl), S(O) 2 NH 2 , S(O) 2 NH(C 1-4 alkyl), S(O) 2 N(C 1-4 alkyl) 2 , C(O)(C 1-4 alkyl), C(O)NH 2 , C(O)NH(C
- R 10 , R 11 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 and R 21 are, independently, hydrogen, C 1-4 alkyl or C 3-7 cycloalkyl;
- R 1 is hydrogen, Ci -6 alkyl, phenyl, pyridinylC(O), C 3-6 cycloalkyl, (C 3-6 cycloalkyl)CH 2 or C 3- 4 alkenyl;
- L is a bond, C 1-4 alkylene (optionally substituted by C 1-4 alkyl or C 1-4 haloalkyl), C 1-4 alkylene-NH (optionally substituted by C 1-4 alkyl or C 1-4 haloalkyl), CH 2 C(O)NH, CH(CH 3 )C(O)NH, Ci -4 alkylene-0 (optionally substituted by C 1-4 alkyl or C 1-4 haloalkyl), C 1 - 4 alkylene-S (optionally substituted by C 1-4 alkyl or C 1-4 haloalkyl), Ci -4 alkylene-S(O) (optionally substituted by Ci -4 alkyl or C 1-4 haloalkyl) or C 1-4 alkylene-S(O) 2 (optionally substituted by C 1-4 alkyl or Ci -4 haloalkyl);
- W is cyclohexyl, phenyl, methylenedioxyphenyl, thienyl, pyrazolyl, thiazolyl, isoxazolyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, 1,3,5-triazinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, benzofuranyl, benzthienyl, indolyl, indolinyl, dihydroindolinyl, indazolyl, benzimidazolyl, benzoxazolyl, benzthiazolyl, quinolinyl, tetrahydroquinolinyl, isoquinolinyl, quinoxalinyl, quinazolinyl, cinnolinyl, phthalazinyl, [l,8]-naphthiridinyl, [l,6]-naphthi
- W is optionally substituted by halo, C 1-6 alkyl, C 1-6 alkoxy, C 1-4 alkylthio, C 1-4 fluoroalkyl, C 1 . 4 fluoroalkoxy, nitro, cyano, OH, C(O) 2 H, C(O) 2 (C 1-4 alkyl), S(O) 2 (Ci -4 alkyl), S(O) 2 NH 2 , S(O) 2 NH(C 1-4 alkyl), S(O) 2 N(Ci -4 alkyl) 2 , benzyloxy, imidazolyl, C(O)(Ci -4 allcyl), C(O)NH 2 , C(O)NH(Ci -4 alkyl), C(O)N(Ci -4 alkyl) 2 , NHC(O)(Ci -4 alkyl) OrNR 12 R 13 ; R 12 and R 13 are, independently, hydrogen, Ci -4 alkyl or C 3-7 cycloal
- Suitable salts include acid addition salts such as a hydrochloride, hydrobromide, phosphate, acetate, fumarate, maleate, tartrate, citrate, oxalate, methanesulphonate, p- toluenesulphonate, succinate, glutarate or malonate.
- the compounds of formula (I) may exist as solvates (such as hydrates) and the present invention covers all such solvates.
- Alkyl groups and moieties are straight or branched chain and are, for example, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl or tert-butyl.
- Haloalkyl comprises, for example, 1 to 6, such as 1, 2, 3, 4 or 5 halogen (such as fluorine or chlorine) atoms. It is, for example, CHF 2 , CF 3 , CH 2 CF 3 , C 2 F 5 or CH 2 Cl.
- Haloalkoxy comprises, for example, 1 to 6, such as 1, 2, 3, 4 or 5 halogen (such as fluorine or chlorine) atoms. It is, for example, OCHF 2 , OCF 3 , OCH 2 CF 3 , OC 2 F 5 or OCH 2 Cl.
- Fluoroalkyl comprises, for example, 1 to 6, such as 1, 2, 3, 4 or 5 fluorine atoms. It is, for example, CHF 2 , CF 3 , CH 2 CF 3 or C 2 F 5 .
- Fluoroalkoxy comprises, for example, 1 to 6, such as 1, 2, 3, 4 or 5 fluorine atoms. It is, for example, OCHF 2 , OCF 3 , OCH 2 CF 3 or OC 2 F 5 .
- Cycloalkyl is for example, cyclopropyl, cyclopentyl or cyclohexyl.
- the present invention provides a compound of formula (I), wherein A is phenyl, naphthyl, pyridinyl, thienyl, quinolinyl or isoquinolinyl, and A is optionally substituted by halo, C 1-6 alkyl, C 1-6 alkoxy, C 1-4 alkylthio, CF 3 , OCF 3 , pyridinyloxy, benzyloxy, nitro, cyano, C(O) 2 H, C(O) 2 (Ci -4 alkyl), S(O) 2 (Ci -4 alkyl), S(O) 2 (Ci -4 alkyl), S(O) 2 NH 2 , S(O) 2 NH(C 1-4 alkyl), S(O) 2 N(C 1-4 alkyl) 2 , C(O)(Cj -4 alkyl), C(O)NH 2 , C(O)NH(C 1-4 alkyl), C(O)N(Cj
- the present invention provides a compound of formula (I), wherein A is phenyl, naphthyl, thienyl, quinolinyl or isoquinolinyl, and A is optionally substituted by halo, Ci -6 alkyl, Ci -6 alkoxy, Ci -4 alkylthio, CF 3 , OCF 3 , phenoxy (optionally substituted by halo or Ci -4 alkyl), phenyl (optionally substituted by halo or Ci -4 alkyl), pyridinyloxy, benzyloxy, nitro, cyano, S(O) 2 NH 2 , C(O)(C 1-4 alkyl), C(O)NH 2 , NHC(O)(C 1-4 alkyl) or NR 10 R 11 ; R 10 and R 11 are, independently, hydrogen, Cj -4 alkyl or C 3-7 cycloalkyl; R 1 is hydrogen, Ci -6 alkyl, phenyl,
- the present invention provides a compound of formula (I) wherein: A is phenyl, naphthyl, thienyl, quinolinyl or isoquinolinyl, and A is optionally substituted by halo (such as fluoro, chloro or bromo), Cj -6 alkyl, C 1-6 alkoxy, nitro, phenoxy (optionally substituted by C 1-4 alkyl), phenyl (optionally substituted by halo (such as fluoro)), pyridinyloxy Or N(C 1-4 alkyl) 2 ; R 1 is hydrogen, C 1-6 alkyl, phenyl, pyridylC(O), cyclohexyl, cyclohexylCH 2 or C 3-4 alkenyl, L is a bond, C 1-4 alkylene (optionally substituted by C 1-4 alkyl), C 1-4 alkylene-NH (optionally substituted by C 1-4 alkyl), CH 2 C
- the present invention provides a compound of formula (I) wherein A is phenyl, naphthyl, pyridinyl, thienyl, quinolinyl or isoquinolinyl, and A is optionally substituted by halo, C 1-6 alkyl, C 1-6 alkoxy, Ci -4 alkylthio, CF 3 , OCF 3 , pyridinyloxy, benzyloxy, nitro, cyano, C(O) 2 H, C(O) 2 (C 1-4 alkyl), S(O) 2 (C 1-4 alkyl), S(O) 2 (C 1-4 alkyl), S(O) 2 NH 2 , S(O) 2 NH(C 1-4 alkyl), S(O) 2 N(C 1-4 alkyl) 2 , C(O)(C 1-4 alkyl), C(O)NH 2 , C(O)NH(C 1-4 alkyl), C(O)N(Ci -4 alkyl
- the present invention provides a compound of formula (I) wherein: A is phenyl, naphthyl, thienyl, quinolinyl or isoquinolinyl, and A is optionally substituted by halo, C 1-6 alkyl, Ci -6 alkoxy, C 1-4 alkylthio, CF 3 , OCF 3 , phenoxy (optionally substituted by halo or C 1-4 alkyl), phenyl (optionally substituted by halo or C 1-4 alkyl), pyridinyloxy, benzyloxy, nitro, cyano, S(O) 2 NH 2 , C(O)(C 1-4 alkyl), C(O)NH 2 , NHC(O)(C 1-4 alkyl) or NR 10 R 11 ; R 10 and R 11 are, independently, hydrogen, C 1-4 alkyl or C 3-7 cycloalkyl; R 1 is hydrogen, Ci -6 alkyl, phenyl
- the present invention provides a compound of formula (I) wherein A is phenyl (optionally substituted by halogen, Ci -4 alkyl, C 1-4 haloalkyl, Ci -4 alkoxy or Ci -4 haloalkoxy), pyridyl (optionally substituted by halogen, Ci -4 alkyl, C 1-4 haloalkyl, Ci -4 alkoxy or C 1-4 haloalkoxy) or pyrazolyl (optionally substituted by C 1-4 alkyl, C 1-4 haloalkyl or phenyl (itself optionally substituted by halogen, C 1-4 alkyl, C 1-4 haloalkyl, Ci -4 alkoxy or C 1-4 haloalkoxy)).
- the invention provides a compound of formula (I) wherein L is C 3 alkylene (substituted by Ci -4 alkyl or Ci -4 haloalkyl), C 2-4 alkylene-NH (substituted by Ci -4 alkyl or C 1-4 haloalkyl), CH 2 C(O)NH, CH(CH 3 )C(O)NH, C 2-4 alkylene-0 (substituted by C 1-4 alkyl or Ci -4 haloalkyl), C 2-4 alkylene-S (substituted by Ci -4 alkyl or Ci -4 haloalkyl), C 2-4 alkylene-S(O) (optionally substituted by Ci -4 alkyl or Ci -4 haloalkyl) or C 2-4 alkylene-S(O) 2 (optionally substituted by C 1-4 alkyl or C 1-4 haloalkyl); wherein C 1-4 alkyl is, for example, methyl or ethyl;
- the invention provides a compound of formula (I) wherein L is C 3 alkylene (substituted by C 1-4 alkyl or Cj -4 haloalkyl), C 2-4 alkylene-NH (substituted by C 1-4 alkyl or C 1-4 haloalkyl) or C 2-4 alkylene-0 (substituted by C 1-4 alkyl or Ci -4 haloalkyl); wherein C 1-4 alkyl is, for example, methyl or ethyl; and C 1-4 haloalkyl is, for example, CF 3 .
- the invention provides a compound of formula (I) wherein L is C 3 alkylene (substituted by Ci -4 alkyl), C 2 alkylene-NH (substituted by Ci -4 alkyl) or C 2 alkylene- O (substituted by Cj -4 alkyl); wherein Ci -4 alkyl is, for example, methyl or ethyl.
- L is, for example, C 2 alkylene-NH (substituted by Ci -4 alkyl).
- L is, for example, C 2 alkylene-0 (substituted by Ci -4 alkyl).
- the invention provides a compound of formula (I) wherein L is CH(CH 3 )CH 2 CH 2 (such as in the S-configuration), CH(CH 3 )CH 2 NH (such as in the S- configuration), CH(CH 3 )CH 2 O (such as in the S -configuration), CH(C 2 H 5 )CH 2 CH 2 (such as in the S-configuration), CH(C 2 H 5 )CH 2 NH (such as in the S-configuration), CH(C 2 H 5 )CH 2 O (such as in the S-configuration) or CH(CF 3 )CH 2 CH 2 (such as in the S-configuration).
- the present invention provides a compound of formula (I) wherein L is CH(CH 3 )CH 2 NH (such as in the S-configuration) or it provides a compound of formula (I) wherein L is CH(CH 3 )CH 2 O (such as in the S-configuration).
- the present invention provides a compound of formula (I) wherein W is phenyl, pyridyl, indolyl (for example indol-4-yl, indol-5-yl, indol-6-yl or indol- 7-yl), indazolyl (for example indazol-4-yl, indazol-5-yl, indazol-6-yl or indazol-7-yl), quinolinyl (for example quinolin-5-yl) or isoquinolinyl (for example isoquinolin-5-yl).
- W is phenyl, pyridyl, indolyl (for example indol-4-yl, indol-5-yl, indol-6-yl or indol- 7-yl), indazolyl (for example indazol-4-yl, indazol-5-yl, indazol-6-yl or indazol
- the present invention provides a compound of formula (I) wherein W is indolyl (for example indol-4-yl, indol-5-yl, indol-6-yl or indol-7-yl), indazolyl (for example indazol-4-yl, indazol-5-yl, indazol-6-yl or indazol-7-yl), quinolinyl (for example quinolin-5-yl) or isoquinolinyl (for example isoquinolin-5-yl).
- W is indolyl (for example indol-4-yl, indol-5-yl, indol-6-yl or indol-7-yl), indazolyl (for example indazol-4-yl, indazol-5-yl, indazol-6-yl or indazol-7-yl), quinolinyl (for example quinolin-5-yl) or isoquinol
- the present invention provides a compound of formula (I) wherein W is indol-4-yl, indol-5-yl, indol-6-yl, indol-7-yl, indazol-4-yl, indazol-5-yl, indazol- 6-yl, indazol-7-yl, quinolin-5-yl or isoquinolin-5-yl.
- the present invention provides a compound of formula (I) wherein W is indazol-4-yl, indazol-5-yl, indazol-6-yl, indazol-7-yl or quinolin-5-yl.
- W is optionally substituted by halogen, C 1-4 alkyl, CF 3 , Ci -4 alkoxy, OCF 3 , phenyl (itself optionally substituted by halogen, Ci -4 alkyl, CF 3 , C 1-4 alkoxy or OCF 3 ) or C(O)NH 2 .
- the present invention provides a compound of formula (I) wherein L is C 1-4 alkylene (optionally substituted by Cu 4 alkyl) or Ci -4 alkylene-0 (optionally substituted by C 1-4 alkyl); for example L is CH(CH 3 )CH 2 O, CH 2 CH 2 O, CH(CH 3 )(CH 2 ) 2 or
- L is C 1-4 alkylene (optionally substituted by Ci -4 alkyl) or C 1-4 alkylene-0 (optionally substituted by Ci -4 alkyl).
- the present invention provides a compound of formula (I) wherein R 1 is hydrogen.
- the present invention provides a compound of formula (I) wherein W is methylenedioxyphenyl, benzofuranyl, benzthienyl, indolyl, indolinyl, dihydroindolinyl, benzimidazolyl, benzoxazolyl, benzthiazolyl, quinolinyl, tetrahydroquinolinyl, isoquinolinyl, quinoxalinyl, quinazolinyl, cinnolinyl, phthalazinyl, [l,8]-naphthiridinyl or [l,6]-naphthiridinyl, optionally substituted as defined above.
- W is linked to L by a ring-carbon in the benzene ring part of its structure (see for example, Example 77, 78, 79, 80 or 83).
- the present invention provides a compound of formula (I) wherein: A is phenyl, naphthyl or thienyl, and A is optionally substituted by halo, C 1-6 alkyl, C 1-6 alkoxy, C 1-4 alkylthio, CF 3 , OCF 3 , phenoxy (optionally substituted by halo or C 1-4 alkyl), phenyl (optionally substituted by halo or C 1-4 alkyl), pyridinyloxy, benzyloxy, nitro, cyano, S(O) 2 NH 2 , C(O)(C 1-4 alkyl), C(O)NH 2 , NHC(O)(Ci -4 alkyl) OrNR 10 R 11 ; R 10 and R 11 are, independently, hydrogen, C 1-4 alkyl or C 3-7 cycloalkyl; R 1 is hydrogen; L is C 1-4 alkylene (optionally substituted by Ci -4 alkyl) or C
- the present invention provides a compound of formula (I) wherein: A is phenyl, naphthyl or thienyl, and A is optionally substituted by halo, C 1-6 alkyl, C 1-6 alkoxy, CF 3 , OCF 3 , phenoxy (optionally substituted by halo or Ci -4 alkyl), phenyl (optionally substituted by halo or Ci -4 alkyl), pyridinyloxy, nitro or cyano; R 1 is hydrogen; L is C 1-4 alkylene (optionally substituted by C 1-4 alkyl) or C 1-4 alkylene-0 (optionally substituted by C 1-4 alkyl); W is phenyl optionally substituted by halo, C 1-6 alkyl, C 1-6 alkoxy, CF 3 , OCF 3 , nitro or cyano; or a pharmaceutically acceptable salt thereof.
- the present invention provides a compound of formula (I) wherein A is phenyl, naphthyl, pyridinyl, furyl, thienyl, isoxazolyl, pyrazolyl, benzthienyl, quinolinyl or isoquinolinyl, and A is optionally substituted by halo, C 1-6 alkyl, C 1-6 alkoxy, C 1-4 alkylthio, C 1-4 fluoroalkyl, C 1-4 fiuoroalkoxy, pyridinyloxy, benzyloxy, nitro, cyano, C(O) 2 H, C(O) 2 (C 1-4 alkyl), S(O) 2 (C 1-4 alkyl), S(O) 2 (C 1-4 alkyl), S(O) 2 NH 2 , S(O) 2 NH(C 1-4 alkyl), S(O) 2 N(C 1-4 alkyl) 2 , C(O)(C 1-4 alkyl),
- the present invention provides a compound of formula (I) wherein A is phenyl (optionally substituted by halogen, C 1-4 alkyl, Ci -4 haloalkyl, Ci -4 alkoxy or Ci -4 haloalkoxy), pyridyl (optionally substituted by halogen, Ci -4 alkyl, Ci -4 haloalkyl, C 1-4 alkoxy or Ci -4 haloalkoxy) or pyrazolyl (optionally substituted by Ci -4 alkyl, Ci -4 haloalkyl or phenyl (itself optionally substituted by halogen, C 1-4 alkyl, Ci -4 haloalkyl, Ci -4 alkoxy or C 1-4 haloalkoxy)); R 1 is hydrogen; L is C 3 alkylene (substituted by C 1-4 alkyl or Ci -4 haloalkyl), C 2- 4 alkylene-NH (substituted by Ci -4 alkyl
- the present invention provides a compound of formula (I) wherein A is phenyl (optionally substituted by halogen, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 alkoxy or Ci -4 haloalkoxy), pyridyl (optionally substituted by halogen, Ci -4 alkyl, Ci -4 haloalkyl, C 1-4 alkoxy or C 1-4 haloalkoxy) or pyrazolyl (optionally substituted by Ci -4 alkyl, Ci -4 haloalkyl or phenyl (itself optionally substituted by halogen, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 alkoxy or C 1-4 haloalkoxy)); R 1 is hydrogen; L is C 3 alkylene (substituted by C 1-4 alkyl or C 1-4 haloalkyl), C 2- 4 alkylene-NH (substituted by C 1-4 alky
- the present invention provides a compound of formula (I) wherein A is phenyl, naphthyl, pyridinyl, furyl, thienyl, isoxazolyl, pyrazolyl, benzthienyl, quinolinyl or isoquinolinyl, and A is optionally substituted by halo, C 1-6 alkyl, C 1-6 aikoxy, C 1-4 alkylthio, C M fluoroalkyl, C 1-4 fluoroalkoxy, pyridinyloxy, benzyloxy, nitro, cyano, C(O) 2 H, C(O) 2 (C 1-4 alkyl), S(O) 2 (C 1-4 alkyl), S(O) 2 (C 1-4 alkyl), S(O) 2 NH 2 , S(O) 2 NH(C 1-4 alkyl), S(O) 2 N(C 1-4 alkyl) 2 , C(O)(C 1-4 alkyl),
- the present invention provides a compound of formula (I) wherein A is phenyl (optionally substituted by halogen, Ci -4 alkyl, C 1-4 haloalkyl, C 1-4 alkoxy or C 1-4 haloalkoxy), pyridyl (optionally substituted by halogen, C 1-4 alkyl, Ci -4 haloalkyl, C 1-4 alkoxy or C 1-4 haloalkoxy) or pyrazolyl (optionally substituted by Ci -4 alkyl, Ci -4 haloalkyl or phenyl (itself optionally substituted by halogen, Ci -4 alkyl, C 1-4 haloalkyl, C 1-4 alkoxy or C 1-4 haloalkoxy)); R 1 is hydrogen; L is CH(CH 3 )CH 2 CH 2 (such as in the S-configuration), CH(CH 3 )CH 2 NH (such as in the S-configuration), CH(CH 3 )CH 2 O (
- the present invention provides a compound of formula (I) wherein A is phenyl (optionally substituted by halogen, C 1-4 alkyl, Ci -4 haloalkyl, C 1-4 alkoxy or C 1-4 haloalkoxy), pyridyl (optionally substituted by halogen, C 1-4 alkyl, C 1-4 haloalkyl, Ci -4 alkoxy or C 1-4 haloalkoxy) or pyrazolyl (optionally substituted by C 1-4 alkyl, C 1-4 haloalkyl or phenyl (itself optionally substituted by halogen, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 alkoxy or Ci -4 haloalkoxy)); R 1 is hydrogen; L is CH(CH 3 )CH 2 CH 2 (such as in the S-configuration), CH(CH 3 )CH 2 NH (such as in the S-configuration), CH(CH 3 )CH 2 O
- the present invention provides a compound of formula (I) wherein A is phenyl, naphthyl, pyridinyl, furyl, thienyl, isoxazolyl, pyrazolyl, benzthienyl, quinolinyl or isoquinolinyl, and A is optionally substituted by halo, C 1-6 alkyl, Ci -6 alkoxy, C 1-4 alkylthio, Ci -4 fluoroalkyl, Ci -4 fluoroalkoxy, pyridinyloxy, benzyloxy, nitro, cyano, C(O) 2 H, C(O) 2 (C 1-4 alkyl), S(O) 2 (Ci -4 alkyl), S(O) 2 NH 2 , S(O) 2 NH(Ci -4 alkyl), S(O) 2 N(C 1-4 alkyl) 2 , C(O)(C 1-4 alkyl), C(O)NH 2 , C(O)
- the present invention provides a compound of formula (I) wherein A is phenyl (optionally substituted by halogen, Ci -4 alkyl, C 1-4 haloalkyl, C 1-4 alkoxy or C 1-4 haloalkoxy), pyridyl (optionally substituted by halogen, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 alkoxy or C 1-4 haloalkoxy) or pyrazolyl (optionally substituted by C 1-4 alkyl, Ci -4 haloalkyl or phenyl (itself optionally substituted by halogen, Ci -4 alkyl, C 1-4 haloalkyl, C 1-4 alkoxy or C 1-4 haloalkoxy)); R 1 is hydrogen; L is CH(CH 3 )CH 2 NH (such as in the S-configuration) or L is CH(CH 3 )CH 2 O (such as in the S-configuration); W is phenyl,
- the present invention provides a compound of formula (I) wherein A is phenyl (optionally substituted by halogen, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 alkoxy or C 1-4 haloalkoxy), pyridyl (optionally substituted by halogen, C 1-4 alkyl, Q -4 haloalkyl, Ci -4 alkoxy or Ci -4 haloalkoxy) or pyrazolyl (optionally substituted by Ci -4 alkyl, C 1-4 haloalkyl or phenyl (itself optionally substituted by halogen, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 alkoxy or C 1-4 haloalkoxy)); R 1 is hydrogen; L is CH(CH 3 )CH 2 NH (such as in the S -configuration) or L is CH(CH 3 )CH 2 O (such as in the S-configuration); W is indazol
- the present invention provides a compound: 4-Bromo-N-( 1 -methyl-3-phenyl-propyl)-benzenesulfonamide; 4-Chloro-N-( 1 -methyl-3-phenyl-propyl)-benzenesulfonamide; 4-Bromo-2-methyl-N-(l-methyl-3-phenyl-propyl)-benzenesulfonamide; N-(I -Methyl-3 -phenyl-propyl)-4-trifluoromethoxy-benzenesulfonamide; 4-Methoxy-2,3 ,6-trimethyl-N-( 1 -methyl-3 -phenyl-propyl)-benzenesulfonamide; 4-tert-Butyl-N-(l-methyl-3-phenyl-propyl)-benzenesulfonamide; N-(l-Methyl-3-phenyl-propyl)-4-phenoxy-benzenes
- Naphthalene-2-sulfonic acid [2-(2,6-dimethyl-phenoxy)- 1 -methyl-ethyl]-amide
- Naphthalene-2-sulfonic acid (3-phenyl-propyl)-amide
- the compounds of formula (I) can be prepared using or adapting methods disclosed in the art, or by using or adapting the method disclosed in the Examples below.
- Starting materials for the preparative methods are either commercially available or can be prepared by literature methods, adapting literature methods.
- a compound of the invention can be prepared by coupling a compound of formula (II):
- Y is a leaving group (for example chlorine), with a compound of formula (III):
- N-L-W (in) ⁇ in a suitable solvent such as tetrahydrofuran or N,N-dimethylformamide
- a suitable solvent such as tetrahydrofuran or N,N-dimethylformamide
- the invention further provides processes for the preparation of the compounds of formula (I). Because of their ability to bind to the glucocorticoid receptor the compounds of formula (I) are useful as anti-inflammatory agents, and can also display antiallergic, immunosuppressive and antiproliferative actions.
- a compound of formula (I), or a pharmaceutically acceptable salt thereof can be used as a medicament for the treatment or prophylaxis of one or more of the following pathologic conditions (disease states) in a mammal (such as a human): (i) Lung diseases, which coincide with inflammatory, allergic and/or proliferative processes:
- collagen diseases of other origins for example systemic lupus erythematodes, sclerodermia, polymyositis, dermatomyositis, polyarteritis nodosa, temporal arteritis
- Gastrointestinal diseases which coincide with inflammatory, allergic and/or proliferative processes:
- otitis externa for example caused by contact dermatitis, infection, etc.
- cerebral edema mainly tumor-induced cerebral edema
- the compounds of formula (I) can also be used to treat disorders such as: Conies Syndrome, primary and secondary hyperaldosteronism, increased sodium retention, increased magnesium and potassium excretion (diuresis), increased water retention, hypertension (isolated systolic and combined systolic/diastolic), arrhythmias, myocardial fibrosis, myocardial infarction, Bartter's Syndrome, disorders associated with excess catecholamine levels, diastolic and systolic congestive heart failure (CHF), peripheral vascular disease, diabetic nephropathy, cirrhosis with edema and ascites, oesophageal varicies, Addison's Disease, muscle weakness, increased melanin pigmentation of the skin, weight loss, hypotension, hypoglycemia, Cushing's Syndrome, obesity, hypertension, glucose intolerance, hyperglycemia, diabetes mellitus, osteoporosis, poly
- CHF congestive heart failure
- 'congestive heart disease refers to a disease state of the cardiovascular system whereby the heart is unable to efficiently pump an adequate volume of blood to meet the requirements of the body's tissues and organ systems.
- CHF is characterized by left ventricular failure (systolic dysfunction) and fluid accumulation in the lungs, with the underlying cause being attributed to one or more heart or cardiovascular disease states including coronary artery disease, myocardial infarction, hypertension, diabetes, valvular heart disease, and cardiomyopathy.
- diastolic congestive heart failure refers to a state of CHF characterized by impairment in the ability of the heart to properly relax and fill with blood.
- systolic congestive heart failure refers to a state of CHF characterized by impairment in the ability of the heart to properly contract and eject blood.
- physiological disorders may present as a “chronic” condition, or an “acute” episode.
- chronic means a condition of slow progress and long continuance.
- a chronic condition is treated when it is diagnosed and treatment continued throughout the course of the disease.
- acute means an exacerbated event or attack, of short course, followed by a period of remission.
- the treatment of physiological disorders contemplates both acute events and chronic conditions. In an acute event, compound is administered at the onset of symptoms and discontinued when the symptoms disappear.
- the present invention provides the use of a compound or formula (I), or a pharmaceutically acceptable salt thereof, for use in therapy (such as a therapy described above).
- the present invention provides the use of a compound or formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of a glucocorticoid receptor mediated disease state (such as a disease state described above).
- the invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of an inflammatory (such as an arthritic) condition.
- the invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of an asthmatic or dermatological condition.
- the invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of COPD.
- the present invention further provides a method of treating a glucocorticoid receptor mediated disease state in a mammal (such as man), which comprises administering to a mammal in need of such treatment an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof.
- a compound of formula (I), or a pharmaceutically acceptable salt thereof for the therapeutic treatment of a mammal, said active ingredient is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, (active ingredient) and a pharmaceutically acceptable adjuvant, diluent or carrier.
- the present invention provides a process for the preparation of said composition comprising mixing the active ingredient with a pharmaceutically acceptable adjuvant, diluent or carrier.
- the pharmaceutical composition can comprise from 0.05 to 99 %w (per cent by weight), for example from 0.05 to 80 %w, such as from 0.10 to 70 %w (for example from 0.10 to 50 %w), of active ingredient, all percentages by weight being based on total composition.
- a pharmaceutical composition of the present invention can be administered in a standard manner for the disease condition that it is desired to treat, for example by topical (such as to the lung and/or airways or to the skin), oral, rectal or parenteral administration.
- a the compound of formula (I), or a pharmaceutically acceptable salt thereof may be formulated into the form of, for example, an aerosol, a powder (for example dry or dispersible), a tablet, a capsule, a syrup, a granule, an aqueous or oily solution or suspension, an (lipid) emulsion, a suppository, an ointment, a cream, drops, or a sterile injectable aqueous or oily solution or suspension.
- a suitable pharmaceutical composition of this invention is one suitable for oral administration in unit dosage form, for example a tablet or capsule containing between O.lmg and Ig of active ingredient.
- composition of the invention is one suitable for intravenous, subcutaneous, intraarticular or intramuscular injection.
- Buffers such as polyethylene glycol, polypropylene glycol, glycerol or ethanol or complexing agents such as hydroxy-propyl ⁇ - cyclodextrin may be used to aid formulation.
- the above formulations may be obtained by conventional procedures well known in the pharmaceutical art. Tablets may be enteric coated by conventional means, for example to provide a coating of cellulose acetate phthalate.
- the invention further relates to combination therapies or compositions wherein a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, is administered concurrently (possibly in the same composition) or sequentially with an agent for the treatment of any one of the above disease states.
- a compound of the invention can be combined with a TNF- ⁇ inhibitor (such as an anti-TNF monoclonal antibody (such as Remicade, CDP- 870 and D.sub2.E.sub7.), or a TNF receptor immunoglobulin molecule (such as Enbrel.reg.)), a non-selective COX-I / COX-2 inhibitor (such as piroxicam or diclofenac; a propionic acid such as naproxen, flubiprofen, fenoprofen, ketoprofen or ibuprofen; a fenamate such as mefenamic acid, indomethacin, sulindac or apazone; a pyrazolone such as phenylbutazone; or a salicylate such as aspirin), a COX-2 inhibitor (such as mel
- the present invention still further relates to the combination of a compound of the invention together with:
- a leukotriene biosynthesis inhibitor such as zileuton, ABT-761, fenleuton, tepoxalin, Abbott-79175, Abbott-85761, an N-(5-substituted)-thiophene-2- alkylsulfonamide, a 2,6-di-tert-butylphenol hydrazones, a methoxytetrahydropyran such as Zeneca ZD-2138, SB-210661, a pyridinyl-substituted 2-cyanonaphthalene compound such as L-739,010; a 2-cyanoquinoline compound such as L-746,530; an indole or quinoline compound such as MK-591, MK-886 or BAY x 1005;
- a receptor antagonist for a leukotriene LTB.sub4., LTC.sub4., LTD.sub4. or LTE.sub4. selected from the group consisting of a phenothiazin-3-one such as L- 651,392; an amidino compound such as CGS-25019c; a benzoxalamine such as ontazolast; a benzenecarboximidamide such as BIIL 284/260; or a compound such as zafirlukast, ablukast, montelukast, pranlukast, verlukast (MK-679), RG-12525, Ro- 245913, iralukast (CGP 45715A) or BAY x 7195;
- a phenothiazin-3-one such as L- 651,392
- an amidino compound such as CGS-25019c
- a benzoxalamine such as ontazolast
- a PDE4 inhibitor including an inhibitor of the isoform PDE4D
- an antihistaminic H.subl . receptor antagonist such as cetirizine, loratadine, desloratadine, fexofenadine, astemizole, azelastine or chlorpheniramine; a gastroprotective H.sub2.
- an ⁇ .subl.- and ⁇ .sub2.- adrenoceptor agonist vasoconstrictor sympathomimetic agent such as propylhexedrine, phenylephrine, phenylpropanolamine, pseudoephedrine, naphazoline hydrochloride, oxymetazoline hydrochloride, tetrahydrozoline hydrochloride, xylometazoline hydrochloride or ethylnorepinephrine hydrochloride; an anticholinergic agent such as ipratropium bromide, tiotropium bromide, oxitropium bromide, pirenzepine or telenzepine; a ⁇ .subl.- to ⁇ .sub4.-adrenoceptor agonist (such as ⁇ 2 adrenoceptor agonist) such as metaproterenol, isoproterenol, isoprenaline, albuterol, sal
- MMP- 13 collagenase-3
- MMP-3 stromelysin- 1
- MMP-10 stromelysin-2
- MMP-I l stromelysin-3
- MMP-12 a modulator of chemokine receptor function such as CCRl, CCR2, CCR2A, CCR2B,
- CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCRlO and CCRIl for the C-C family
- CXCRl, CXCR2, CXCR3, CXCR4 and CXCR5 for the C-X-C family
- CX 3 CRl for the C-X 3 -C family
- an osteoporosis agent such as raloxifene, droloxifene, lasofoxifene or fosomax
- an immunosuppressant agent such as FK-506, rapamycin, cyclosporine, azathioprine or methotrexate
- a compound useful in the treatment of AIDS and/or HIV infection for example: an agent which prevents or inhibits the viral protein gpl20 from engaging host cell CD4
- ⁇ such as soluble CD4 (recombinant); an anti-CD4 antibody (or modified / recombinant antibody) for example PRO542; an anti-groupl20 antibody (or modified / recombinant antibody); or another agent which interferes with the binding of group 120 to CD4 for example BMS 806 ⁇ ; an agent which prevents binding to a chemokine receptor, other than CCR5, used by the HIV virus ⁇ such as a CXCR4 agonist or antagonist or an anti-CXCR4 antibody ⁇ ; a compound which interferes in the fusion between the HIV viral envelope and a cell membrane ⁇ such as an anti- group 41 antibody; enfuvirtide (T-20) or T- 1249 ⁇ ; an inhibitor of DC-SIGN (also known as CD209) ⁇ such as an anti-DC-SIGN antibody or an inhibitor of DC-SIGN binding ⁇ ; a nucleoside/nucleotide analogue reverse transciptase inhibitor ⁇ for example zidovudine
- the present invention still further relates to the combination of a compound of the invention together with: (i) a tryptase inhibitor; (ii) a platelet activating factor (PAF) antagonist; (iii) an interleukin converting enzyme (ICE) inhibitor; (iv) an IMPDH inhibitor; (v) an adhesion molecule inhibitor including a VLA-4 antagonist; (vi) a cathepsin; (vii) a MAP kinase inhibitor; (viii) a glucose-6 phosphate dehydrogenase inhibitor; (ix) a kinin- B.subl. - and B.sub2.
- a -receptor antagonist comprising: (x) an anti-gout agent, e.g., colchicine; (xi) a xanthine oxidase inhibitor, e.g., allopurinol; (xii) an uricosuric agent, e.g., probenecid, sulfinpyrazone or benzbromarone; (xiii) a growth hormone secretagogue; (xiv) a transforming growth factor (TGF ⁇ ); (xv) a platelet-derived growth factor (PDGF); (xvi) a fibroblast growth factor, e.g., basic fibroblast growth factor (bFGF); (xvii) a granulocyte macrophage colony stimulating factor (GM-CSF); (xviii) a capsaicin cream; (xix) a Tachykinin NK.
- an anti-gout agent e.g., colchicine
- NKP-608C sub 1. and NK.sub3. receptor antagonist selected from the group consisting of NKP-608C; SB-233412 (talnetant); and D-4418;
- an elastase inhibitors selected from the group consisting of UT- 77 and ZD-0892;
- TACE TNF ⁇ converting enzyme inhibitor
- iNOS induced nitric oxide synthase inhibitor
- a chemoattractant receptor-homologous molecule expressed on TH2 cells a CRTH2 antagonist.
- NMP l-Methyl-2-pyrrolidinone app approximately sat saturated aq aqueous
- Method A Instrument Agilent 1100; Column C 18 Waters Symmetry 2.1 x 30 mm 3.5 ⁇ m; Flow rate 0.7 ml/min; Mass APCI; UV-absorption was measured at 254nm; Solvent A: water + 0.1% TFA; Solvent B: acetonitrile + 0.1% TFA; Gradient 5-95%/B 8 min, 95% B 2 min.
- Method B Instrument Agilent 1100; Column Kromasil C 18 3 x 100 mm 5 ⁇ m; Flow rate 1.0 ml/min; UV-absorption was measured at 254nm; Solvent A: water + 0.1% TFA; Solvent B: acetonitrile + 0.1% TFA; Gradient 10-100%B 20 min, 100% B 1 min.
- Examples 18 - 76 were synthesised by a method analogous to that described in Example 17 using the corresponding starting materials.
- Step 1 (2S)-2-[(Mesitylsulfonyl)amino]propyl 2,4,6-trimethylbenzenesulfonate
- Step 2 N-[(l S)-2-(5-Isoquinolinyloxy)- 1 -methylethyl]-2,4,6-trimethylbenzenesulfonamide (2S)-2-[(Mesitylsulfonyl)amino]propyl 2,4,6-trimethylbenzenesulfonate (263mg, O. ⁇ mmole) was added to a slurry containing Cs 2 CO 3 (487mg, 1.5mmole) and 5- Hydroxyisoquinoline (145mg, lmmole) in 2.5mL DMF.
- reaction mixture was stirred overnight in room teperature before it was diluted with ethyl acetate (2OmL) and washed with lMHCl/aq. The organic layer was dried, concentrated and purified on HPLC-C 18 .
- Examples 78 - 83 were synthesised by a method analogous to that described in Example 77 using (2S)-2-[(mesitylsulfonyl)amino]propyl 2,4,6-trimethylbenzenesulfonate and the corresponding starting materials.
- Examples 85-95 were synthesised by a method analogous to that described in Example 84 using the corresponding starting materials.
- Phthalic anhydride (50mmole, 7.4g) was dissolved in 10OmL toluene together with L- alaninol (50mmole, 3.9mL) and DIEA (5mmole, 900 ⁇ L). The mixture was refluxed with continues removal of water with a Dean-Stark apparatus for two hours before it was washed with IM HCl/aq , sat. NaHCO 3 /aq. The organic layer was dried, concentrated and used in the next step without any further purification. APCI-MS m/z: 206.0 [MH+].
- Examples 97 - 122 were synthesised by a method analogous to that described in Example 96 using the corresponding starting materials.
- Examples 124 — 129 were synthesised by a method analogous to that described in Example 123 using the corresponding starting materials.
- Examples 131-144 were prepared via the aryl ether formation as described in Example 4, using (2S)-2-[(mesitylsulfonyl)amino]propyl 2,4,6-trimethylbenzenesulfonate and the orresponding starting materials.
- TBAT (Llmmole, 594mg) was dissolved in dry THF (12mL) and cooled to 0 0 C under iert conditions.
- 4-methyl-N-[(lZ)-3-phenylpropylidene]- enzenesulfonamide (1 mmole, 287mg) and trimethyl(trifluoromethyl)silane (1.2mmole, 70mg) were dissolved in dry THF (1OmL) and slowly added to the TBAT-solution. The lixture was stirred for 45 min at 0°C before it was quenched with sat. NH 4 Cl/aq (6mL) . At Dom temperature the mixture was extracted with ethylacetate. The organic phase was dried, oncentrated and purified on a silica gel column chromatography (heptane-ethyl acetate).
- Examples 147 to 153 were synthesised by a method analogous to that described in ⁇ xample 146 using the corresponding starting materials.
- Examples 154 to 158 were synthesised by a method analogous to that described in ⁇ xample 96, "Sulfonamide coupling", using the corresponding starting materials. cample 154 -(2-AnilmoethylV2,4,6-trimetliylbenzenesulfonamide
- Example 160 was synthesised using a method analogous to Example 159.
- the title compound was obtained from 2-mesitylenesulfonyl chloride, 2-aminobutan- -ol and quinolin-5-ol by a method analogous to that described in Example 77.
- Examples 164 - 184 were synthesised by a method analogous to that described in ⁇ xample 17 using the corresponding starting materials.
- Examples 186- 194 were synthesised by a method analogous to that described in Example 185 using the corresponding starting materials.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Pharmacology & Pharmacy (AREA)
- Rheumatology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002584413A CA2584413A1 (en) | 2004-10-29 | 2005-10-26 | Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases |
MX2007004862A MX2007004862A (en) | 2004-10-29 | 2005-10-26 | Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases. |
RSP-2007/0076A RS20070076A (en) | 2004-10-29 | 2005-10-26 | Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases |
EP05796607A EP1807391A4 (en) | 2004-10-29 | 2005-10-26 | Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases |
AU2005300150A AU2005300150A1 (en) | 2004-10-29 | 2005-10-26 | Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases |
US11/718,214 US20090093485A1 (en) | 2004-10-29 | 2005-10-26 | Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases |
BRPI0517263-2A BRPI0517263A (en) | 2004-10-29 | 2005-10-26 | New Sulfonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases |
IL182685A IL182685A0 (en) | 2004-10-29 | 2007-04-19 | Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0402636A SE0402636D0 (en) | 2004-10-29 | 2004-10-29 | Chemical compounds |
SE0402636-5 | 2004-10-29 | ||
SE0500651 | 2005-03-22 | ||
SE0500651-5 | 2005-03-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006046916A1 true WO2006046916A1 (en) | 2006-05-04 |
Family
ID=36228080
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/SE2005/001610 WO2006046916A1 (en) | 2004-10-29 | 2005-10-26 | Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases |
Country Status (18)
Country | Link |
---|---|
US (1) | US20090093485A1 (en) |
EP (1) | EP1807391A4 (en) |
KR (1) | KR20070068432A (en) |
AR (1) | AR054702A1 (en) |
AU (1) | AU2005300150A1 (en) |
BR (1) | BRPI0517263A (en) |
CA (1) | CA2584413A1 (en) |
CR (1) | CR9022A (en) |
EC (1) | ECSP077349A (en) |
GT (1) | GT200500307A (en) |
IL (1) | IL182685A0 (en) |
MX (1) | MX2007004862A (en) |
PA (1) | PA8651001A1 (en) |
PE (1) | PE20060932A1 (en) |
RS (1) | RS20070076A (en) |
TW (1) | TW200630326A (en) |
UY (1) | UY29182A1 (en) |
WO (1) | WO2006046916A1 (en) |
Cited By (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007100851A1 (en) * | 2006-02-28 | 2007-09-07 | Helicon Therapeutics, Inc. | Therapeutic compounds |
WO2008010765A1 (en) | 2006-07-19 | 2008-01-24 | Astrazeneca Ab | Novel tricyclic spiropiperidine compounds, their synthesis and their uses as modulators of chemokine receptor activity |
WO2008063116A1 (en) * | 2006-11-23 | 2008-05-29 | Astrazeneca Ab | Indozalyl sulphonamide derivatives useful as glucocorticoid modulators |
WO2008075005A1 (en) | 2006-12-19 | 2008-06-26 | Astrazeneca Ab | Quinuclidinol derivatives as muscarinic receptor antagonists |
WO2008076048A1 (en) * | 2006-12-21 | 2008-06-26 | Astrazeneca Ab | Indazolyl ester and amide derivatives for the treatment of glucocorticoid receptor mediated disorders |
WO2008079073A1 (en) * | 2006-12-22 | 2008-07-03 | Astrazeneca Ab | Indazolyl sulphonamide derivatives for the treatment of glucocorticoid receptor mediated disorders |
WO2009142569A1 (en) * | 2008-05-20 | 2009-11-26 | Astrazeneca Ab | Phenyl or pyridinyl substituted indazoles derivatives |
US7635711B2 (en) | 2004-12-27 | 2009-12-22 | Boehringer-Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
WO2010067102A1 (en) | 2008-12-09 | 2010-06-17 | Astrazeneca Ab | Diazaspiro [5.5] undecane derivatives and related compounds as muscarinic-receptor antagonists and beta-adrenoreceptor agonists for the treatment of pulmonary disorders |
JP2010523689A (en) * | 2007-04-10 | 2010-07-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Glucocorticoid mimetics, process for producing the same, pharmaceutical composition and use thereof |
JP2010523691A (en) * | 2007-04-10 | 2010-07-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Glucocorticoid mimetics, process for producing the same, pharmaceutical composition and use thereof |
US7795272B2 (en) | 2004-03-13 | 2010-09-14 | Boehringer Ingelheim Pharmaceutical, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof |
EP2256117A1 (en) | 2006-11-14 | 2010-12-01 | AstraZeneca AB | Quiniclidine derivatives of (hetero) arylcycloheptanecarboxylic acid as muscarinic receptor antagonists |
WO2011016050A2 (en) | 2009-07-31 | 2011-02-10 | Cadila Healthcare Limited | Novel compounds as modulators of glucocorticoid receptors |
US7932392B2 (en) | 2002-03-26 | 2011-04-26 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
WO2011073662A1 (en) | 2009-12-17 | 2011-06-23 | Astrazeneca Ab | Combination of a benzoxazinone and a further agent for treating respiratory diseases |
EP2364704A1 (en) | 2007-02-08 | 2011-09-14 | AstraZeneca AB | Combination of beta-adrenoceptor agonist and corticosteroid |
US8119809B2 (en) | 2007-11-16 | 2012-02-21 | Rigel Pharmaceuticals, Inc. | AMPK-activating heterocycloalkyloxy(hetero)aryl carboxamide, sulfonamide and amine compounds and methods for using the same |
US8129390B2 (en) | 2007-12-12 | 2012-03-06 | Rigel Pharmaceuticals, Inc. | Carboxamide, sulfonamide and amine compounds and methods for using the same |
US8268859B2 (en) | 2008-06-06 | 2012-09-18 | Boehringer Ingelheim International Gmbh | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof |
US8329729B2 (en) | 2008-05-13 | 2012-12-11 | Astrazeneca Ab | Quinuclidine derivatives as muscarinic M3 receptor antagonists |
US8501745B2 (en) | 2006-02-28 | 2013-08-06 | Dart Neuroscience (Cayman) Ltd. | Piperazine PDE4 inhibitors and uses thereof |
US8658637B2 (en) | 2006-12-06 | 2014-02-25 | Boehringer Ingelheim International Gmbh | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof |
US8741897B2 (en) | 2003-09-24 | 2014-06-03 | Boehringer Ingelheim Pharmaceuticals Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof |
EP2778156A1 (en) | 2008-05-27 | 2014-09-17 | AstraZeneca AB (Publ) | Phenoxypyridinylamide derivatives and their use in the treatment of PDE4 mediated disease states |
WO2015017906A1 (en) * | 2013-08-09 | 2015-02-12 | Fundação Oswaldo Cruz | Diphenyloxyalkylamine derivatives and aryloxyalkylamine derivatives, pharmaceutical composition, use of said pharmaceutical composition for treating, preventing or inhibiting chronic pulmonary inflammatory diseases and method for treating or preventing such diseases |
EP2865664A4 (en) * | 2012-06-20 | 2016-05-11 | Bamichem Co Ltd | Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient |
US9458118B2 (en) | 2013-09-10 | 2016-10-04 | Chromocell Corporation | Sodium channel modulators for the treatment of pain and diabetes |
US9616037B2 (en) | 2008-09-19 | 2017-04-11 | Pimco 2664 Limited | Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use |
US9624167B2 (en) | 2013-06-26 | 2017-04-18 | Pimco 2664 Limited | N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamides and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamides and their therapeutic use |
US9650349B2 (en) | 2007-08-27 | 2017-05-16 | Dart Neuroscience (Cayman) Ltd. | Therapeutic isoxazole compounds |
US10005733B2 (en) | 2014-12-17 | 2018-06-26 | Pimco 2664 Limited | N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)-benzenesulfonamide compounds and their therapeutic use |
US10179781B2 (en) | 2013-03-15 | 2019-01-15 | Chromocell Corporation | Sodium channel modulators for the treatment of pain |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2013200480B2 (en) * | 2006-02-28 | 2016-06-09 | Dart Neuroscience (Cayman) Ltd. | Therapeutic compounds |
KR101377419B1 (en) * | 2010-05-25 | 2014-03-26 | 안국약품 주식회사 | Novel derivatives inhibiting activity of 11beta-HSD1 (11β-Hydroxysteroid dehydrogenase type 1) enzyme, preparation method thereof and pharmaceutical composition containing the same as an active ingredient |
WO2011149213A2 (en) * | 2010-05-25 | 2011-12-01 | 주식회사 이큐스앤자루 | Novel derivative having inhibitory activity against 11β-hsd1, preparation method thereof, and pharmaceutical composition containing same as active ingredient |
EP2925717A4 (en) * | 2012-11-28 | 2016-08-03 | Stichting Dienst Landbouwkundi | Benzenesulfonamide compounds for somatic embryogenesis i plants |
US20230339851A1 (en) * | 2022-03-21 | 2023-10-26 | Chemocentryx, Inc. | Cxcr6 sulfonamide compounds |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0201735A1 (en) * | 1985-04-24 | 1986-11-20 | Bayer Ag | N-indolylethyl sulfon amides, process for their preparation and their use |
US4948809A (en) * | 1985-10-02 | 1990-08-14 | Boehringer Mannheim Gmbh | Sulphonylalkylamines, processes for the preparation thereof and pharmaceutical compositions containing them |
EP0569193B1 (en) * | 1992-05-06 | 1997-02-26 | E.R. SQUIBB & SONS, INC. | N-isoxazole-phenylsulfonamide derivatives and their use as endothelin antagonists |
EP0558258B1 (en) * | 1992-02-24 | 1997-05-07 | E.R. SQUIBB & SONS, INC. | N-isoxazole-naphthylsulfonamide derivatives and their use as endothelin antagonists |
US5861401A (en) * | 1994-03-31 | 1999-01-19 | Zeneca Limited | N-heterocyclyl sulphonamide derivatives and their use as endothelin antagonists |
EP1190710A1 (en) * | 1999-05-13 | 2002-03-27 | Shionogi & Co., Ltd. | Preventive or therapeutic drugs for diabetes |
WO2004019935A1 (en) * | 2002-08-29 | 2004-03-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | -3 (sulfonamidoethyl) -indole derivaties for use as glucocorticoid mimetics in the treatment of inflammatory, allergic and proliferative diseases |
WO2005077895A1 (en) * | 2004-02-17 | 2005-08-25 | Ishihara Sangyo Kaisha, Ltd. | Thioamides and salts thereof and cytokine production inhibitors containing both |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3992441A (en) * | 1972-12-26 | 1976-11-16 | Pfizer Inc. | Sulfamylbenzoic acids |
DE3000377A1 (en) * | 1980-01-07 | 1981-07-09 | Boehringer Mannheim Gmbh, 6800 Mannheim | NEW SULPHONAMIDES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS |
EP1554239B1 (en) * | 2002-10-11 | 2011-01-26 | Actelion Pharmaceuticals Ltd. | Sulfonylamino-acetic acid derivatives and their use as orexin receptor antagonists |
-
2005
- 2005-10-26 BR BRPI0517263-2A patent/BRPI0517263A/en not_active Application Discontinuation
- 2005-10-26 KR KR1020077009609A patent/KR20070068432A/en not_active Application Discontinuation
- 2005-10-26 EP EP05796607A patent/EP1807391A4/en not_active Withdrawn
- 2005-10-26 AU AU2005300150A patent/AU2005300150A1/en not_active Abandoned
- 2005-10-26 US US11/718,214 patent/US20090093485A1/en not_active Abandoned
- 2005-10-26 RS RSP-2007/0076A patent/RS20070076A/en unknown
- 2005-10-26 CA CA002584413A patent/CA2584413A1/en not_active Abandoned
- 2005-10-26 MX MX2007004862A patent/MX2007004862A/en not_active Application Discontinuation
- 2005-10-26 WO PCT/SE2005/001610 patent/WO2006046916A1/en active Application Filing
- 2005-10-27 GT GT200500307A patent/GT200500307A/en unknown
- 2005-10-27 AR ARP050104507A patent/AR054702A1/en not_active Application Discontinuation
- 2005-10-28 TW TW094137733A patent/TW200630326A/en unknown
- 2005-10-28 PA PA20058651001A patent/PA8651001A1/en unknown
- 2005-10-28 UY UY29182A patent/UY29182A1/en not_active Application Discontinuation
- 2005-10-28 PE PE2005001262A patent/PE20060932A1/en not_active Application Discontinuation
-
2007
- 2007-03-27 EC EC2007007349A patent/ECSP077349A/en unknown
- 2007-03-28 CR CR9022A patent/CR9022A/en not_active Application Discontinuation
- 2007-04-19 IL IL182685A patent/IL182685A0/en unknown
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0201735A1 (en) * | 1985-04-24 | 1986-11-20 | Bayer Ag | N-indolylethyl sulfon amides, process for their preparation and their use |
US4948809A (en) * | 1985-10-02 | 1990-08-14 | Boehringer Mannheim Gmbh | Sulphonylalkylamines, processes for the preparation thereof and pharmaceutical compositions containing them |
EP0558258B1 (en) * | 1992-02-24 | 1997-05-07 | E.R. SQUIBB & SONS, INC. | N-isoxazole-naphthylsulfonamide derivatives and their use as endothelin antagonists |
EP0569193B1 (en) * | 1992-05-06 | 1997-02-26 | E.R. SQUIBB & SONS, INC. | N-isoxazole-phenylsulfonamide derivatives and their use as endothelin antagonists |
US5861401A (en) * | 1994-03-31 | 1999-01-19 | Zeneca Limited | N-heterocyclyl sulphonamide derivatives and their use as endothelin antagonists |
EP1190710A1 (en) * | 1999-05-13 | 2002-03-27 | Shionogi & Co., Ltd. | Preventive or therapeutic drugs for diabetes |
WO2004019935A1 (en) * | 2002-08-29 | 2004-03-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | -3 (sulfonamidoethyl) -indole derivaties for use as glucocorticoid mimetics in the treatment of inflammatory, allergic and proliferative diseases |
WO2005077895A1 (en) * | 2004-02-17 | 2005-08-25 | Ishihara Sangyo Kaisha, Ltd. | Thioamides and salts thereof and cytokine production inhibitors containing both |
Non-Patent Citations (3)
Title |
---|
DATABASE REGISTRY [online] XP008113735, accession no. STN Database accession no. 321722-44-5 * |
RN 321704-10-3, RN 321704-02-3, RN 321703-82-6, 321703-77-9, 321703-75-7 * |
See also references of EP1807391A4 * |
Cited By (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7932392B2 (en) | 2002-03-26 | 2011-04-26 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
US8212040B2 (en) | 2002-03-26 | 2012-07-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and thereof |
US8741897B2 (en) | 2003-09-24 | 2014-06-03 | Boehringer Ingelheim Pharmaceuticals Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof |
US7795272B2 (en) | 2004-03-13 | 2010-09-14 | Boehringer Ingelheim Pharmaceutical, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof |
US7741361B2 (en) | 2004-12-27 | 2010-06-22 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
US7635711B2 (en) | 2004-12-27 | 2009-12-22 | Boehringer-Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
US8501745B2 (en) | 2006-02-28 | 2013-08-06 | Dart Neuroscience (Cayman) Ltd. | Piperazine PDE4 inhibitors and uses thereof |
WO2007100851A1 (en) * | 2006-02-28 | 2007-09-07 | Helicon Therapeutics, Inc. | Therapeutic compounds |
US7919626B2 (en) | 2006-02-28 | 2011-04-05 | Helicon Therapeutics, Inc. | Pyrazole compounds and uses thereof |
US8791137B2 (en) | 2006-02-28 | 2014-07-29 | Dart Neuroscience (Cayman) Ltd. | Therapeutic compounds |
US8399487B2 (en) | 2006-02-28 | 2013-03-19 | Dart Neuroscience (Cayman) Ltd. | Pyrazole compounds and uses thereof |
EP2465850A1 (en) * | 2006-02-28 | 2012-06-20 | Helicon Therapeutics, Inc. | Therapeutic compounds |
WO2008010765A1 (en) | 2006-07-19 | 2008-01-24 | Astrazeneca Ab | Novel tricyclic spiropiperidine compounds, their synthesis and their uses as modulators of chemokine receptor activity |
US8207193B2 (en) | 2006-11-14 | 2012-06-26 | Astrazeneca Ab | Quiniclidine derivatives of (hetero) arylcycloheptanecarboxylic acid as muscarinic receptor antagonists |
EP2256117A1 (en) | 2006-11-14 | 2010-12-01 | AstraZeneca AB | Quiniclidine derivatives of (hetero) arylcycloheptanecarboxylic acid as muscarinic receptor antagonists |
US8030340B2 (en) | 2006-11-23 | 2011-10-04 | Astrazeneca Ab | Indazolyl sulphonamide derivatives useful as glucocorticoid modulators |
WO2008063116A1 (en) * | 2006-11-23 | 2008-05-29 | Astrazeneca Ab | Indozalyl sulphonamide derivatives useful as glucocorticoid modulators |
JP2010510985A (en) * | 2006-11-23 | 2010-04-08 | アストラゼネカ・アクチエボラーグ | Indazolylsulfonamide derivatives useful as glucocorticoid modulators |
CN101646654B (en) * | 2006-11-23 | 2012-03-28 | 阿斯利康(瑞典)有限公司 | Indozalyl sulphonamide derivatives useful as glucocorticoid modulators |
US8658637B2 (en) | 2006-12-06 | 2014-02-25 | Boehringer Ingelheim International Gmbh | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof |
WO2008075005A1 (en) | 2006-12-19 | 2008-06-26 | Astrazeneca Ab | Quinuclidinol derivatives as muscarinic receptor antagonists |
EA016895B1 (en) * | 2006-12-21 | 2012-08-30 | Астразенека Аб | Indazolyl ester and amide derivatives for the treatment of glucocorticoid receptor mediated disorders |
WO2008076048A1 (en) * | 2006-12-21 | 2008-06-26 | Astrazeneca Ab | Indazolyl ester and amide derivatives for the treatment of glucocorticoid receptor mediated disorders |
US7728030B2 (en) | 2006-12-21 | 2010-06-01 | Astrazeneca Ab | Chemical compounds 572 |
US8143290B2 (en) | 2006-12-21 | 2012-03-27 | Astrazeneca Ab | Chemical compounds 572 |
TWI417094B (en) * | 2006-12-21 | 2013-12-01 | Astrazeneca Ab | Chemical compounds 572 |
WO2008079073A1 (en) * | 2006-12-22 | 2008-07-03 | Astrazeneca Ab | Indazolyl sulphonamide derivatives for the treatment of glucocorticoid receptor mediated disorders |
EP2364704A1 (en) | 2007-02-08 | 2011-09-14 | AstraZeneca AB | Combination of beta-adrenoceptor agonist and corticosteroid |
JP2010523691A (en) * | 2007-04-10 | 2010-07-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Glucocorticoid mimetics, process for producing the same, pharmaceutical composition and use thereof |
JP2010523689A (en) * | 2007-04-10 | 2010-07-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Glucocorticoid mimetics, process for producing the same, pharmaceutical composition and use thereof |
US10053467B2 (en) | 2007-08-27 | 2018-08-21 | Dart Neuroscience (Cayman) Ltd. | Therapeutic isoxazole compounds |
US9650349B2 (en) | 2007-08-27 | 2017-05-16 | Dart Neuroscience (Cayman) Ltd. | Therapeutic isoxazole compounds |
US9174964B2 (en) | 2007-11-16 | 2015-11-03 | Rigel Pharmaceuticals, Inc. | AMPK-activating piperidinyloxy-substituted 2,3-dihydro-1H-indene-1-amine compounds and pharmaceutical compositions including the same |
US8119809B2 (en) | 2007-11-16 | 2012-02-21 | Rigel Pharmaceuticals, Inc. | AMPK-activating heterocycloalkyloxy(hetero)aryl carboxamide, sulfonamide and amine compounds and methods for using the same |
US8569340B2 (en) | 2007-11-16 | 2013-10-29 | Rigel Pharmaceuticals, Inc. | AMPK-activating piperidinyloxypyiridine carboxamide and sulfonamide compounds and methods for using the same |
US8895578B2 (en) | 2007-12-12 | 2014-11-25 | Rigel Pharmaceuticals, Inc. | Carboxamide, sulfonamide and amine compounds and methods for using the same |
US8557822B2 (en) | 2007-12-12 | 2013-10-15 | Rigel Pharmaceuticals, Inc. | Carboxamide, sulfonamide and amine compounds and methods for using the same |
US8129390B2 (en) | 2007-12-12 | 2012-03-06 | Rigel Pharmaceuticals, Inc. | Carboxamide, sulfonamide and amine compounds and methods for using the same |
US8329729B2 (en) | 2008-05-13 | 2012-12-11 | Astrazeneca Ab | Quinuclidine derivatives as muscarinic M3 receptor antagonists |
US9512110B2 (en) | 2008-05-20 | 2016-12-06 | Astrazeneca Ab | Phenyl and benzodioxinyl substituted indazoles derivatives |
US8211930B2 (en) | 2008-05-20 | 2012-07-03 | Astrazeneca Ab | Phenyl and benzodioxinyl substituted indazoles derivatives |
EA018629B8 (en) * | 2008-05-20 | 2013-12-30 | Астразенека Аб | Phenyl and benzodioxinyl substituted indazoles derivatives |
EA018629B1 (en) * | 2008-05-20 | 2013-09-30 | Астразенека Аб | Phenyl and benzodioxinyl substituted indazoles derivatives |
WO2009142569A1 (en) * | 2008-05-20 | 2009-11-26 | Astrazeneca Ab | Phenyl or pyridinyl substituted indazoles derivatives |
JP2011520955A (en) * | 2008-05-20 | 2011-07-21 | アストラゼネカ・アクチエボラーグ | Phenyl and benzodioxinyl substituted indazole derivatives |
JP2014185188A (en) * | 2008-05-20 | 2014-10-02 | Astrazeneca Ab | Phenyl- and benzodioxynyl-substituted indazole derivative |
US9738632B2 (en) | 2008-05-20 | 2017-08-22 | Astrazeneca Ab | Phenyl and benzodioxinyl substituted indazoles derivatives |
US8916600B2 (en) | 2008-05-20 | 2014-12-23 | Astrazeneca Ab | Phenyl and benzodioxinyl substituted indazoles derivatives |
WO2009142571A1 (en) * | 2008-05-20 | 2009-11-26 | Astrazeneca Ab | Phenyl and benzodioxinyl substituted indazoles derivatives |
EP2778156A1 (en) | 2008-05-27 | 2014-09-17 | AstraZeneca AB (Publ) | Phenoxypyridinylamide derivatives and their use in the treatment of PDE4 mediated disease states |
US8268859B2 (en) | 2008-06-06 | 2012-09-18 | Boehringer Ingelheim International Gmbh | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof |
US9616037B2 (en) | 2008-09-19 | 2017-04-11 | Pimco 2664 Limited | Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use |
WO2010067102A1 (en) | 2008-12-09 | 2010-06-17 | Astrazeneca Ab | Diazaspiro [5.5] undecane derivatives and related compounds as muscarinic-receptor antagonists and beta-adrenoreceptor agonists for the treatment of pulmonary disorders |
WO2011016050A2 (en) | 2009-07-31 | 2011-02-10 | Cadila Healthcare Limited | Novel compounds as modulators of glucocorticoid receptors |
WO2011073662A1 (en) | 2009-12-17 | 2011-06-23 | Astrazeneca Ab | Combination of a benzoxazinone and a further agent for treating respiratory diseases |
EP2865664A4 (en) * | 2012-06-20 | 2016-05-11 | Bamichem Co Ltd | Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient |
US10179781B2 (en) | 2013-03-15 | 2019-01-15 | Chromocell Corporation | Sodium channel modulators for the treatment of pain |
US10029979B2 (en) | 2013-06-26 | 2018-07-24 | Pimco 2664 Limited | N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamides and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamides and their therapeutic use |
US10233147B2 (en) | 2013-06-26 | 2019-03-19 | Pimco 2664 Limited | N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamides and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamides and their therapeutic use |
US9624167B2 (en) | 2013-06-26 | 2017-04-18 | Pimco 2664 Limited | N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamides and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamides and their therapeutic use |
US9796670B2 (en) | 2013-06-26 | 2017-10-24 | Pimco 2664 Limited | N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamides and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamides and their therapeutic use |
WO2015017906A1 (en) * | 2013-08-09 | 2015-02-12 | Fundação Oswaldo Cruz | Diphenyloxyalkylamine derivatives and aryloxyalkylamine derivatives, pharmaceutical composition, use of said pharmaceutical composition for treating, preventing or inhibiting chronic pulmonary inflammatory diseases and method for treating or preventing such diseases |
JP2016527280A (en) * | 2013-08-09 | 2016-09-08 | ファンダサウン オズワルド クルス | Diphenyloxyalkylamine derivatives and aryloxyalkylamine derivatives, pharmaceutical compositions, use of said pharmaceutical compositions for treating, preventing or preventing chronic pulmonary inflammatory diseases, and treating or preventing such diseases Way for |
US9458118B2 (en) | 2013-09-10 | 2016-10-04 | Chromocell Corporation | Sodium channel modulators for the treatment of pain and diabetes |
US10005733B2 (en) | 2014-12-17 | 2018-06-26 | Pimco 2664 Limited | N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)-benzenesulfonamide compounds and their therapeutic use |
Also Published As
Publication number | Publication date |
---|---|
AR054702A1 (en) | 2007-07-11 |
EP1807391A4 (en) | 2010-01-06 |
IL182685A0 (en) | 2007-09-20 |
ECSP077349A (en) | 2007-04-26 |
CA2584413A1 (en) | 2006-05-04 |
BRPI0517263A (en) | 2008-10-07 |
KR20070068432A (en) | 2007-06-29 |
MX2007004862A (en) | 2007-05-09 |
PA8651001A1 (en) | 2006-06-02 |
RS20070076A (en) | 2008-09-29 |
CR9022A (en) | 2007-10-04 |
PE20060932A1 (en) | 2006-10-13 |
US20090093485A1 (en) | 2009-04-09 |
AU2005300150A1 (en) | 2006-05-04 |
EP1807391A1 (en) | 2007-07-18 |
TW200630326A (en) | 2006-09-01 |
UY29182A1 (en) | 2006-05-31 |
GT200500307A (en) | 2006-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1807391A1 (en) | Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases | |
US20110130426A1 (en) | Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases | |
US9738632B2 (en) | Phenyl and benzodioxinyl substituted indazoles derivatives | |
JP4898428B2 (en) | New compounds | |
AU2003297398B2 (en) | Asthma and allergic inflammation modulators | |
US20090124607A1 (en) | Novel Bicyclic Sulfonamides for Use as Glucocorticoid Receptor Modulators in the Treatment of Inflammatory Diseases | |
US8030340B2 (en) | Indazolyl sulphonamide derivatives useful as glucocorticoid modulators | |
EA018121B1 (en) | Pyrimidine derivatives for the treatment of asthma, copd, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, cancer, hepatitis b, hepatitis c, hiv, hpv, bacterial infections and dermatosis | |
US20090170898A1 (en) | Sulphonamide Derivatives as Modulators of the Glucocorticoid Receptor | |
JP2013047189A (en) | Novel parabanic acid derivative, and medicine containing the same as effective component | |
EP1193250A1 (en) | Phenyl sulfamate derivatives | |
WO2008079073A1 (en) | Indazolyl sulphonamide derivatives for the treatment of glucocorticoid receptor mediated disorders | |
US20200115357A1 (en) | Liver x receptors (lxr) modulators | |
US20040029928A1 (en) | Novel propenohydroxamic acid derivatives | |
WO2008087514A2 (en) | Hdac inhibitors | |
CN101094832A (en) | Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases | |
AU2004251104B2 (en) | N-{'4-substituted piperazine-1-sulfonylmethyl!alkyl}-N-hydroxyfomamide compounds as metalloproteinase inhibitors | |
US20090036484A1 (en) | Use of Unsaturated Quionoline or Naphtalene Derivatives as Medicaments | |
CN1845894B (en) | Phenoxiacetic acid derivatives | |
US20120065173A1 (en) | Chemical compounds | |
US20120220590A1 (en) | Novel compounds as modulators of glucocorticoid receptors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV LY MD MG MK MN MW MX MZ NA NG NO NZ OM PG PH PL PT RO RU SC SD SG SK SL SM SY TJ TM TN TR TT TZ UG US UZ VC VN YU ZA ZM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SZ TZ UG ZM ZW AM AZ BY KG MD RU TJ TM AT BE BG CH CY DE DK EE ES FI FR GB GR HU IE IS IT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: P-2007/0076 Country of ref document: RS |
|
WWE | Wipo information: entry into national phase |
Ref document number: CR2007-009022 Country of ref document: CR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005300150 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2584413 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 182685 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005796607 Country of ref document: EP Ref document number: MX/a/2007/004862 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 07040958 Country of ref document: CO |
|
ENP | Entry into the national phase |
Ref document number: 2005300150 Country of ref document: AU Date of ref document: 20051026 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 554755 Country of ref document: NZ |
|
WWP | Wipo information: published in national office |
Ref document number: 2005300150 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12007500919 Country of ref document: PH Ref document number: 3196/DELNP/2007 Country of ref document: IN Ref document number: 1020077009609 Country of ref document: KR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007538859 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007115547 Country of ref document: RU Ref document number: A20070578 Country of ref document: BY |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580045404.1 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2005796607 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11718214 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0517263 Country of ref document: BR |